MNTA  Momenta Pharmaceuticals Inc.

Exchange

NASDAQ

Sector

Health Care

Industry

Biotechnology: Biological Products (No Diagnostic Substances)

Market Cap.

745.3M

Vuru Grade

31.00/100

Current Price

$13.98
+0.33 (+2.42%)

Stability Price

$0.29
Overvalued by 97.90%

Company Metrics

  • 13.83 P/E
  • 13.93 P/S
  • 3.53 P/B
  • -1.91 EPS
  • -146.29% Cash ROIC
  • 11.20 Cash Ratio
  • 0 / 0% Dividend
  • 702,838.00 Avg. Vol.
  • 53.31M Shares
  • 745.3M Market Cap.

Company Description

Momenta Pharmaceuticals, Inc., a biotechnology company, specializes in the in the characterization and process engineering of complex molecules. These complex molecules include proteins, polypeptides, and cell surface polysaccharides, such as heparan-sulfate proteoglycans (HSPGs). The company applies its technology for the development of generic versions of complex drug products, as well as for th...
more


Download 10 Years of Financial Statements:
Income Statement   Balance Sheet   Cash Flow

News

Momenta Pharmaceuticals Announces Publication Revealing Development of a ...
GlobeNewswire (press release) - 16 hours ago
CAMBRIDGE, Mass., March 2, 2015 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that results from preclinical ...
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) Update: Momenta announces ... - Wall Street Pulse
Why Momenta Pharmaceuticals, Inc. Jumped Higher Today
Motley Fool - Feb 19, 2015
Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
Momenta Pharmaceuticals to Webcast Presentation at Cowen and Company's ... - MarketWatch
Momenta Pharmaceuticals Reports Fourth Quarter and Year End 2014 Financial ... - GlobeNewswire (press release)
Momenta Pharmaceuticals, Inc. Pushes Forward
Motley Fool - Nov 5, 2014
At this point, earnings calls for Momenta Pharmaceuticals (NASDAQ: MNTA ) are more an opportunity to update investors than to report revenue and earnings.
Momenta Pharmaceuticals Reports Third Quarter 2014 Financial Results - MarketWatch
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results ... - Seeking Alpha (registration)
Momenta Pharmaceuticals Inc. (MNTA): New Analyst Report from Zacks Equity ...
Nasdaq - Feb 4, 2015
Cambridge, MA-based Momenta Pharmaceuticals, Inc. is a biotechnology company focused on designing products on the basis of a complex systems analysis platform, analyzing data to assess the biological function of these products and developing ...
Momenta Pharmaceuticals, Inc. Receives Average Target Price of $14 - Bar and Graph Report
Momenta Pharmaceuticals Announces Date of Fourth Quarter and Year End ... - MarketWatch
Momenta Pharmaceuticals Inc. (MNTA) is Trading Higher on Unusual Volume for ...
Equities.com - Feb 25, 2015
Momenta Pharmaceuticals Inc. ($MNTA) experienced unusually high volume on Feb. 25, as the stock gained 4.91% to a closing price of $13.89.
Earnings Preview: MGM Resorts International, Momenta Pharmaceuticals, Inc ...
Schaeffers Research (blog) - Feb 13, 2015
Elsewhere, short-term calls are popular in Momenta Pharmaceuticals, Inc.'s options pits, per its Schaeffer's call/put open interest ratio (SOIR) of 0.19, which sits in the 12th percentile of its annual range.
Momenta Pharmaceuticals Inc. (MNTA) is Trading Lower on Unusual Volume for ...
Equities.com - Feb 19, 2015
Momenta Pharmaceuticals Inc. ($MNTA) experienced unusually high volume on Feb. 19, as the stock [gained/lost] 3% to a closing price of $13.41.
Company Shares of Momenta Pharmaceuticals, Inc. Rally 11.2%
Ashburn Daily - Feb 22, 2015
Shares of Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) rose by 11.2% in the past week and 22.39% for the last 4 weeks.
Why Momenta Pharmaceuticals, Inc. Shares Sank
Motley Fool - May 6, 2014
What: Shares of Momenta Pharmaceuticals (NASDAQ: MNTA ) , a biotechnology company primarily engaged in the development of biosimilar and generic compounds, dipped as much as 13% after the company reported its first-quarter results before the ...
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q1 2014 Results ... - Seeking Alpha
Time to Pick Up the Momenta Pharmaceuticals Pieces (RDY, TEVA, MNTA) - SmallCap Network
Revenue Update on Momenta Pharmaceuticals, Inc.
Ashburn Daily - Feb 25, 2015
Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) announced the earnings results for Fiscal Year 2014 and Quarter 4. The results came in during pre-market on February 17,2015.
Momenta Pharmaceuticals President Craig A. Wheeler Sells 2110 Shares (MNTA) - The Legacy
Insider Selling: Craig A. Wheeler Sells 2110 Shares of Momenta ... - Dakota Financial News